Similar to prior studies in this field searching for predictive AAbs in NSCLC treated with ICIs, such as NY-ESO-1 (22, 23), these three AAbs (MAX, DHX29, and TAPBP) exhibit positive correlations with favorable outcomes, including fewer progression events, longer PFS, and OS. Here, MAX is linked to non-small cell lung carcinoma.